Please ensure Javascript is enabled for purposes of website accessibility

Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday

By Cory Renauer – Aug 6, 2021 at 2:43PM

Key Points

  • Dicerna Pharmaceuticals is developing RNA interference drugs similar to successful products from Alnylam.
  • Dicerna Pharmaceuticals wanted to market nedosiran to primary hypoxia type 2 patients because Oxlumo from Alnylam is already a popular treatment option for the limited type 1 population.
  • Phase 2 trial results from the first six evaluable type 2 patients were deeply disappointing.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A less than satisfying result from a phase 2 trial with nedosiran makes the company's future difficult to predict.

What happened

Shares of Dicerna Pharmaceuticals (DRNA), a clinical-stage biopharmaceutical company, are tanking after a phase 2 clinical trial readout with the company's lead candidate, nedosiran. Investors left wondering about the company's next move pushed the stock 27.4% lower as of 2:22 p.m. EDT on Friday.

So what 

Dicerna Pharmaceuticals is developing nedosiran as a treatment for primary hypoxia (PH) types 1 and 2. Patients with this rare disorder produce too much oxalate that forms lots of painful kidney stones.

Investment advisor explaining a sinking stock chart.

Image source: Getty Images.

Last November, the FDA approved Oxlumo, a drug from Alnylam (ALNY -2.90%) that interferes with the production of an enzyme specific to PH1 patients. This is why investors hoped Dicerna's candidate would show efficacy for the still underserved PH2 population. 

The stock is getting beaten down today because the phase 2 trial results showed encouraging oxalate knockdowns for PH1 patients but not for the PH2 group. Among five PH2 patients, treatment with nedosiran led to a slight increase in urinary oxalate levels. One PH2 patient who received a placebo actually showed an improvement of more than 40%. 

Now what

With such a small number of PH2 patients evaluated so far, there's still a slight chance that nedosiran has a chance at treating this underserved population. Given the data we've seen from the first six, though, it seems Dicerna won't be able to file for accelerated approval of nedosiran as a PH2 treatment this year.

Dicerna Pharmaceuticals is also testing nedosiran as a potential treatment for PH3 patients with results expected in October. There are only an estimated 2,700 Americans with PH1. If PH3 data doesn't save the day, Dicerna could contend with Alnylam and Oxlumo for this extremely limited patient population.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy.

Stocks Mentioned

Dicerna Pharmaceuticals Stock Quote
Dicerna Pharmaceuticals
Alnylam Pharmaceuticals Stock Quote
Alnylam Pharmaceuticals
$219.64 (-2.90%) $-6.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.